Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus® library

Future Medicinal Chemistry

Volumn 4, Issue 18, 2012, Pages 2265-2277

  Paquet, Tanya ^a   Gordon, Richard ^b   Waterson, David ^c   Witty, Michael J ^c   Chibale, Kelly ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Technology Innovation Agency   (South Africa)

^c ICC   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; AMINOPYRIDINE; AMINOPYRIDINE DERIVATIVE; ANTIMALARIAL AGENT; ARTEROLANE; CHLOROQUINE; FERROQUINE; OZ 439; SPIROINDOLONE; THIAZOLE; TRIFLUOROMETHYLPYRIDYL; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTICLE; CELL SCREENING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; LOW DRUG DOSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

AMINOPYRIDINES; ANIMALS; ANTIMALARIALS; DATABASES, PHARMACEUTICAL; DRUG RESISTANCE; HUMANS; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84871094936     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.176     Document Type: Article

References (35)

1. Stepniewska K, White NJ. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52(5), 1589-1596 (2008). (Pubitemid 351614647)
2. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77(6), 181-192 (2007).
3. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 7(12), 864-874 (2009).
4. Wells TNC, Burrows JN, Baird JK. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 26(3), 145-151 (2010).
5. Brewer GJ, Powell RD, Swanson SH, Alving AS. Hemolytic effect of primaquine. XVII. Hexokinase activity of glucose-6-phosphate dehydrogenase-deficient and normal erythrocytes. Lab. Clin. Med. 61, 601-612 (1964).
6. Wells TNC, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug. Discov. 8(11), 879-891 (2009).
7. Rodrigues T, Prudencio M, Moreira R, Mota MM, Lopes F. Targeting the liver stage of malaria parasites: a yet unmet goal. J. Med. Chem. 55(3), 995-1012 (2012).
8. Choi S-R, Mukherjee P, Avery MA. The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr. Med. Chem. 15(2), 161-171 (2008). (Pubitemid 351234619)
9. Burrows JN, Chibale K, Wells TNC. The state of the art in anti-malarial drug discovery and development. Curr. Top. Med. Chem. 11(10), 1226-1254 (2011).
10. Plouffe D, Brinker A, McNamara C et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc. Natl Acad. Sci. USA 105(26), 9059-9064 (2008).
11. Swinney DC, Anthony J. How were new medicines discovered? Nat. Rev. Drug. Discov. 10(7), 507-519 (2011).
12. Chatterjee AK, Yeung BKS. Back to the future: lessons learned in modern target-based and whole-cell lead optimization of antimalarials. Curr. Top. Med. Chem. 12(5), 473-483 (2012).
13. Van Pelt-Koops JC, Pett HE, Graumans W et al. The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob. Agents Chemother. 56(7), 3544-3548 (2012).
14. Charman SA, Arbe-Barnes S, Bathurst IC et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc. Natl Acad. Sci. USA 108(11), 4400-4405 (2011).
15. Vennerstrom JL, Arbe-Barnes S, Brun R et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430(7002), 900-904 (2004). (Pubitemid 39119218)
16. Valecha N, Looareesuwan S, Martensson A et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a Phase II, multicenter, randomized, dose-finding clinical trial. Clin. Infect. Dis. 51(6), 684-691 (2010).
17. Biot C, Glorian G, Maciejewski LA, Brocard JS. Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. J. Med. Chem. 40(23), 3715-3718 (1997). (Pubitemid 27481715)
18. Lee JA, Chu S, Willard FS et al. Open innovation for phenotypic drug discovery: the PD2 assay panel. J. Biomol. Screen. 16(6), 588-602 (2011).
19. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J. Med. Chem. 55(10), 4527-4538 (2012).
20. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug. Discov. 6(1), 29-40 (2007). (Pubitemid 46020284)
21. Guiguemde WA, Shelat AA, Bouck D et al. Chemical genetics of Plasmodium falciparum. Nature 465(9107) 311-315 (2010).
22. Duffy S, Avery VM. Development and optimization of a novel 384-well antimalarial imaging assay validated for high-throughput screening. Am. J. Trop. Med. Hyg. 86(1), 84-92 (2012).
23. Harris CJ, Hill RD, Sheppard DW, Slater MJ, Stouten PFW. The design and application of target-focused compound libraries. Comb. Chem. High Throughput Screen. 14(6), 521-531 (2011).
24. Gonzalez Cabrera D, Douelle F, Feng T-S et al. Novel orally active antimalarial thiazoles. J. Med. Chem. 54(21), 7713-7719 (2011).
25. Younis Y, Douelle F, Feng T-S et al. 3,5-diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential. J. Med. Chem. 55(7), 3479-3487 (2012).
26. Burrows JN, Leroy D, Lotharius J, Waterson D. Challenges in antimalarial drug discovery. Future Med. Chem. 3(11), 1401-1412 (2011).
27. Selwood DL, Brummell DG, Glen RC et al. Solution-phase parallel synthesis of 5-carboxamido 1-benzyl-3-(3-dimethylaminopropyloxy)-1H-pyrazoles as activators of soluble guanylate cyclase with improved oral bioavailability. Bioorg. Med. Chem. Lett. 11(8), 1089-1092 (2001). (Pubitemid 32319988)
28. Persson T, Yde CW, Rasmussen JE et al. Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Org. Biomol. Chem. 5(24), 3963-3970 (2007). (Pubitemid 350205976)
29. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature, 440(4710), 463-469 (2006).
30. Carter R, Diggs CL. Plasmodia of rodents. In: Parasitic Protozoa. Kreier JP (Ed.). Academic Press, New York, NY, USA, 359-465 (1977).
31. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov. 3(6), 509-520 (2004). (Pubitemid 38807533)
32. Peters W. Drug resistance in Plasmodium berghei. I. Chloroquine resistance. Exptl. Parasitol. 17(1), 80-89 (1965).
33. Peters W. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann. Trop. Med. Parasitol. 69(2), 155-171 (1975).
34. Gamo F-J, Sanz LM, Vidal J et al. Thousands of chemical starting points for antimalarial lead identification. Nature 465(9107), 305-310 (2010).
35. Yazdi HH, Janahmadi M, Behzadi G. The role of small-conductance Ca2+-activated K+ channels in the modulation of 4-aminopyridine-induced burst firing in rat cerebellar Purkinje cells. Brain Res. 1156, 59-66 (2007). (Pubitemid 46920508)